Establishment of a novel system for the culture and expansion of hepatic stem-like cancer cells  by Li, Jiang et al.
Original Articles
Establishment of a novel system for the culture and expansion of
hepatic stem-like cancer cells
Jiang Li a,1, Yong Yu b,1, Jinghan Wang b,1, Zi Yan a, Hui Liu a, Ying Wang a, Min Ding a,
Lei Cui a, Mengchao Wu a,c, Xiaoqing Jiang b,*, Qijun Qian a,c,**
a Laboratory of Viral and Gene Therapy Eastern Hepatobiliary Surgical Hospital & Institute, The Second Military University, Shanghai 200438, China
b The First Department of Biliary Surgery, Eastern hepatobiliary Surgical hospital, The Second Military Medical University, Shanghai 200438, China
c Shanghai Engineering Research Center of Cell Therapy, Shanghai 200438, China
A R T I C L E I N F O
Article history:
Received 16 October 2014
Received in revised form 24 December
2014
Accepted 3 February 2015
Keywords:
Liver cancer
Cancer stem cells
Hepatic cancer stem cells
Primary liver tumor
Tumor initiation
A B S T R A C T
Hepatocellular carcinoma (HCC) is a major primary liver malignancy in adults. Despite the progress made,
the outcome of the treatment to this disease is less than satisfactory as the post therapy tumor recur-
rence is almost inevitable. Accumulating pieces of evidence have suggested that the recurrence is due
to the existence of a subpopulation of the HCC cells that possess the properties of stem cells and are
resistant to radiation and chemotherapy. It is therefore important to understand the characteristics of
this subpopulation of HCC cells, and which requires the establishment of an in vitro system to study these
stem-like cancer cells. However, despite extensive efforts, the progress in establishing such an in vitro
system has been slow largely due to the lack of deﬁnitive biomarkers in the isolation and expansion of
these cells. In order to successfully maintain and expand HCC CSCs, we ﬁrst optimized the culture system.
We establish a novel medium system that allows the culture and enrichment of these hepatic stem-like
cancer cells from both hepatoma cells and human primary HCC cells. These cells exhibited typical stem
cell properties, such as enhanced stem cell markers, gain of EMT properties and drug resistance, and more
importantly, stronger tumor-initiating capabilities. The medium may help to establish an in vitro model
for hepatic cancer stem cell (HCSC) studies, which may contribute to the development of novel cell thera-
pies and new drugs for the treatment of HCC.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Hepatocellular carcinoma (HCC) is the most common primary
liver malignancy in adults. It is also the ﬁfth most common solid
cancer worldwide and the third leading cause of cancer related
death [1,2]. Currently, surgical resection is the main option for the
treatment of HCC, but unfortunately, due to resistance to both ra-
diation and chemotherapy, postoperative tumor recurrence is
almost inevitable. There are two theories that attempt to explain
the formation of HCC: the classical clonal evolution model and the
cancer stem cell (CSC) or tumor-initiating cell (TIC) model. The foun-
dation of the TIC model of HCC formation is that HCC is a disease
of adult stem cells. The model postulates the existence of a sub-
population of tumor cells exhibiting the stem cell properties of
self-renewal and differentiation but also showing an innate resis-
tance to radiation and chemotherapy. These cells are often referred
as hepatic cancer stem cells (HCSCs) and they are deﬁned by their
ability to initiate tumor when transplanted into immune-
compromised mice (transplantability) and by their capacity to
recapitulate the heterogeneity of original cells in the primary lesions
where they are derived from. The TIC model has recently received
wide attention because it provides an explanation for resistance
to therapeutic intervention due to the quiescent or slow cycling
HCSCs that may survive the treatment such as radiation and/or
chemotherapy and result in recurrence. This model is also sup-
ported by clinical observations and experimental evidence, as a
subpopulation of HCC cells possesses two functional properties that
are widely accepted to be associated with CSCs: resistance to ra-
diation and chemotherapy and eﬃcient transplant ability [3].
To better understand the etiology of HCC and develop effective
anticancer approaches, there is a clear need of in vitromodel systems
for the study of the HCSCs. In the general CSC ﬁeld, three types of
in vitro models have been established [4]: (a) subpopulations se-
lected from existing tumor lines; (b) cell lines created from tumor
or normal cells by genetic manipulation; and (c) CSCs selected from
tumors or sorted tumor cells using deﬁned serum-free conditions.
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There have been ongoing efforts in identifying and characterizing
these cells. In the last decade, several promising speciﬁc cell surface
markers for putative HCSCs have been identiﬁed including CD133
[5], CD90 [6] and EpCAM [7]. These markers have been used to neg-
atively or positively select for a subpopulation of HCC cells that are
capable of initiating tumor in immune-comprised mice, but still
possess the resistance to radiation and cytotoxic agents. However,
these markers showed different expression patterns in different
subsets of tumor-initiating HCC cells, suggesting the lack of deﬁn-
itive markers for HCSC selection and the heterogeneity of these
HCSCs, which may be activated by different signaling pathways in
normal stem/progenitor cells where these HCSCs may originate.
Another method of HCSC isolation is based on the differential eﬄux
of ﬂuorescent dyes, such as rhodamine 123 or Hoechst 33342.
However, as Hoechst 33342 is cytotoxic, the enrichment of tumor-
initiation abilities of side population (SP) cells is most likely due
to an artifact of Hoechst 33342 toxicity, because these SP cells are
protected by their membrane transport properties; whereas non-
SP cells are unprotected and unable to grow due to the toxicity. Thus,
the enrichment of tumor-initiating SP cells is unlikely due to in-
trinsic stem-cell properties. Recently, the physical properties of the
HCC cells were applied to select HCSCs, in which these cells were
reported to be enriched by density gradient centrifugation [8].
However, the quantity of the cells obtained is limited and the cells
cannot be further enriched with this method.
The selection of CSCs by using deﬁned serum-free culture con-
ditions is a powerful approach to create in vitro models for CSC
expansion and differentiation [9–11]. The strength of this method
is the ability to deﬁne the correct environment (niche) required to
maintain the stemness of the CSCs. This method has been success-
fully used to select and expand cell populations with CSC
characteristics from patients with colon and lung cancers [12] and
gliomas [13]. In this study, we developed a deﬁned serum-free
medium that is able to enrich and expand HCSCs, maintain their
stem cell traits but are still capable of tumor initiation. After ex-
tensive screening, we selected a formula that allows us to culture
HCSCs from both hepatoma cells and primary human HCC cells.
These cultured cells exhibited up-regulated HCSC biomarkers such
as CD90, enhanced epithelial–mesenchymal transition (EMT) prop-
erties, invasive potentials and resistance to chemotherapy drugs.
More importantly, the tumor initiation capability of these cells was
signiﬁcantly increased. Taken together, the medium developed in
this study allows us to effectively enrich the population of HCSCs
from both hepatoma and human primary HCC cells, which may fa-
cilitate the study on HCSCs.
Materials and methods
Primary tumor cell culture
The protocol was approved by the Institutional Review Board of the Eastern
Hepatobiliary Hospital, SecondMilitary Medical University, Shanghai, China. The HCC
biopsies were provided by the Department of Liver Surgery, Eastern Hepatobiliary
Surgical Hospital, Shanghai, China. Written consents were obtained from patients
prior to sample acquisition. The tumor tissues were washed and minced into frag-
ments of 1 × 1 × 1mm3 before being digested in 0.5mg/ml type-I collagenase at 37 °C
for 20–30min tomake a single cell suspension. Cells were thenwashedwith D. Hanks
solution twice, and 1 × 105/ml cells were seeded in petri dishes with 2–3 ml DMEM
supplemented with 10% fetal bovine serum (FBS) or deﬁned serum-free media, and
cultured in a 5% CO2 incubator at 37 °C.
Cell line culture, sphere formation and passage
Human hepatoma cell lines Hep3B and Huh7 were obtained from the Ameri-
can Type Culture Collection (ATCC). MHCC97-L, MHCC97-H [14], and HCCLM3 [15]
were generous gifts from Shanghai Zhongshan Hospital (Shanghai, China). All of the
cells were maintained in DMEM with 10% FBS, 100 IU/ml penicillin G and 100 μg/
ml streptomycin at 37 °C in a 5% CO2 incubator. For suspension sphere culture, cells
were ﬁrst washed with PBS to remove serum, and then suspended in seven deﬁned
serum-free media with formulas summarized in Table S1. Tumor cells at different
passages were plated at ultralow attachment 6-well plates (Corning Inc., Corning,
NY, USA) at a density of 5000 cells/well. The formation of tumor-spheres was ob-
served under an inverted light microscope at 100× and 200× magniﬁcations. The
spheres were collected by gentle centrifugation, then dissociated with trypsin–
EDTA andmechanically disrupted with a pipette. The resulting single cell suspension
was then centrifuged to remove the trypsin–EDTA and re-suspended in serum-
free medium to allow the re-forming of spheres. The spheres were passaged every
5–8 days before they reached a diameter of ~100 μm.
Cell cycle assays
Cell cycle analysis was performed after ﬂuorescence labeling of the cellular DNA
with propidium iodide (PI) (Invitrogen, Carlsbad, CA, USA). After two rinses with cold
PBS, HCC cells were harvested during the exponential growth phase, ﬁxed with cold
70% ethanol, and then incubated at 4 °C for 4 hours. After centrifugation at 1000 rpm
for 3 minutes and being rinsed with cold PBS, cells were resuspended in 1ml PI stain
(50 mM PI, 100 mg/ml RNase) and incubated at room temperature for 30 min. The
cell cycle of the cells was then analyzed by FACS (BD, US).
Invasion assay
The invasive potentials of HCC and sphere-forming cells were compared by using
BioCoat Matrigel invasion chambers (BD, Franklin Lakes, NJ) with 8 μm pore mem-
brane ﬁlters in a 24-well culture plate by following the manufacturer’s instruction.
HCC cells were resuspended at a ﬁnal concentration of 1 × 104 cells/ml in 0.1ml DMEM
containing 1% FBS in the upper chamber. The lower chambers were loadedwith 0.6ml
DMEM containing 10% FBS. After 24 h or 48 h, cells that migrated through theMatrigel
and attached to the bottom of the membrane were ﬁxed and stained with crystal
violet. Migrated cells in three different ﬁelds were counted. Three replicated ex-
periments were performed and error bars represented the standard error of themean.
In vivo tumorigenesis assay
The protocols for in vivo mouse xenograft model were approved by Medical Ex-
perimental Animal Care Unit of the Second Military Medical University. Six to eight
week-old BALB/c nude mice were provided by Shanghai SLAC Laboratory Animal Co.
Ltd of Chinese Academy of Sciences, and the mice were maintained in a pathogen-
free condition. The deﬁned number of parental and sphere-forming cancer cells mixed
with 0.1 ml serum-free DMEM/Matrigel (1:1) was inoculated in the left or right ﬂank
of mice. Tumor growth was monitored every 3 days starting on the third week after
the inoculation. The mice were sacriﬁced at day 90 or when the tumors grew to a
maximum of 1000 mm3. Tumor xenograft volume in mm3 was calculated by the
formula: Volume = (width)2 × length/2.
Chemotherapy sensitivity assays
The sensitivities of the Hep3B and HuH7 parental and sphere-forming cells to
chemotherapeutic drugs were measured by Cell Counting Kit-8 (CCK-8) assay using
WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium. Brieﬂy, 4000 cells/well were seeded in 96-well plates, and various
concentrations of doxorubicin (Sigma-Aldrich) were added at the beginning. After
72 h incubation, viable cells were measured by CCK-8 assay by following the ma-
nufacturer’s instruction.
Quantitative reverse transcription PCR (qRT-PCR)
RNA samples were extracted from both the parental and the sphere cells, cDNA
were synthesized using the Superscript III ﬁrst-strand cDNA synthesis kit (Invitrogen,
Carlsbad, CA). qRT-PCR was carried out using SYBR Green PCR Master Mix. The PCR
protocol was: 95 °C for 10 min, followed by 40 cycles of 95 °C 15 s, 60 °C 60 sec and
72°C 45 sec. The following primers were used:Wnt-1, 5′-TAAGCAGGTTCGTGGAGGAG-
3′ (forward) and 5′-GGTTTCTGCTACGCTGCTG-3′ (reverse); CD90, 5′-TGAAGGT
CCTCTACTTATCCGC-3′ (forward) and 5′-GCACTGTGACGTTCTGGGA-3′ (reverse). Ep-
CAM, 5′-GCTGGGGGAGGGGAGCCTAC-3′ (forward) and 5′-ACTGCTCACCTCTGGCCGCT-
3′ (reverse). NOTCH1, 5′-GTTGGGGTCCTGGCATC-3′ (forward) and 5′-GGTGAGA
CCTGCCTGAATG-3′ (reverse). NOTCH2, 5′-CACAGGGTTCATAGCCATCTC-3′ (forward)
and 5′-GGAGGCGACCGAGAAGAT-3′ (reverse). NOTCH3, 5′-CCTGAGTGACAGGGGTCCT-
3′ (forward) and 5′-TGTGCAAATGGAGGTCGTT-3′ (reverse). Oct4, 5′-GAACCATACT
CGAACCACATCC-3′ (forward), 5′-CGTTCTCTTTGGAAAGGTGTTC-3′ (reverse). Nanog,
5′-TTTGGAAGCTGCTGGGGAAG-3′ (forward), 5′-GATGGGAGGAGGGGAGAGGA-3′
(reverse). CD133, 5′-AGAGCTTGCACCAACAAAGTACAC-3′ (forward), 5′-AAGCA
CAGAGGGTCATTGAGAGA-3’(reverse). CD44, 5′-TGCCGCTTTGCAGGTGTAT-3′ (forward),
5′-GGCCTCCGTCCGAGAGA-3′ (reverse). Beta-Actin, 5′-ATCTGGCACCACACCTTCTACAA-
3′ (forward), 5′-GTACATGGCTGGGGTGTTGAAG-3′ (reverse). Relative gene-expression
quantiﬁcation method was used to calculate the fold change of mRNA expression
according to the comparative Ct method using β-actin as an endogenous control. Final
results were determined as: 2−(ΔCt sample−ΔCt control). Data were represented as ratio or
fold changes to parental cells.
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Immunoﬂuorescence staining
HCC derived adherent cells were labeled with anti-human protein antibodies
(see below) and ﬁxed with 4% paraformaldehyde for 20 minutes. After blocking with
10% Bovine Serum Albumin (BSA) (Sigma Aldrich), cells were incubated overnight
with primary antibodies: anti-human cytokertin 8/18 monoclonal antibody (Abcam),
mouse antihuman E-Cad antibody (Abcam) and mouse antihuman vimentin anti-
body (R&D) and antihuman CD90 monoclonal antibody (Becton Dickinson, Franklin
Lakes, NJ, USA) at the dilution of 1:100. Tyramide signal ampliﬁcation kits (PerkinElmer
Life and Analytical Sciences, Inc.) were used with Cy3 or Cy5 (red/green) ﬂuorescence.
RNA sequencing and data mining
The RNA samples (~50 ng) were ampliﬁed with a MessageAmp II aRNA Ampli-
ﬁcation kit (Ambion) to generatemultiple copies of ampliﬁed RNA (aRNA) by following
the manufacturer’s instruction. After ampliﬁcation, aRNAs were puriﬁed and frag-
mented into small pieces. The cleaved RNA fragments were reverse transcribed into
a single-strand cDNA, followed by second strand DNA synthesis with DNA poly-
merase I. The synthesized double-stranded cDNA fragments were subjected to
puriﬁcation, and then ligated to Illumina adapters using Quick ligation TM kit (NEB)
and DNA ligase. The resultant cDNA adapter-modiﬁed cDNA libraries were ampli-
ﬁed by 15 cycles of polymerase chain reaction. The cDNA libraries were ﬁnally
subjected to cluster formation, primer hybridization and sequencing reactions using
the Illumina Genome Analyzer II (Illumina, San Diego, CA, USA) by following the ma-
nufacturer’s instruction. Raw short sequence fragments were accepted if they passed
the quality ﬁltering parameters used in the Illumina GA Pipeline GERALD stage.
High-quality reads were aligned to the human reference genome (NCBI Build
36.1) using NextGENe® software (Softgenetics, State College, PA, USA). The matched
reads were aligned to Human Refseq mRNA (NCBI). Reads shorter than 20 bps and
those with the quality score less than 14 were excluded. The sequences aligned with
individual transcript were counted digitally. The expression levels for each gene were
normalized to reads per kilobase of exon model per million mapped reads (RPKM)
to facilitate the comparison of transcripts among samples. Large databases contain-
ing all gene transcripts identiﬁed by RNA-Seq for the samples of sphere-forming cells
fromHep3B, Huh7 andMHCC97-H cell lines were assembled. Amean log2 fold change
[RPKM of sphere-forming cancer cells/RPKM of parental cells] of each gene was cal-
culated across all 3 cell lines. The false discovery rate (FDR, i.e. a probability of wrongly
accepting a difference between parental and sphere-forming cancer cells) of each
gene was determined according to the previously reported method [16]. The genes
were regarded as differentially expressed when their FDRs were less than 0.05. Fur-
thermore, genes were classiﬁed as up-regulated when their mean log2 fold change
ratios were larger than 1 or down-regulated when their log2 fold change ratios were
less than −1.
Statistical analysis
Data were collected using an MS-Excel spreadsheet. Group comparisons for con-
tinuous data were done with Student’s t-test for independent means or two-way
ANOVA. All experiments were performed in triplicate. Statistical signiﬁcance was
set at P < 0.05.
Results
Optimization of the culture medium and expansion of sphere-
forming cells from various human liver cancer cells
In order to successfully maintain and expand HCC CSCs, we ﬁrst
optimized the culture system. After careful examination, seven ef-
ﬁcient culture systems (Table S1) were selected to be further
assessed. In these culture media, cells generally formed non-
adherent, three-dimensional sphere clusters. We ﬁnally determined
that C3 formula is the most suitable culture system, which con-
tains DMEM/F12, Neurobasal-A medium, B27 without VA, EGF and
the cytokines FGF-10 and IGF-1. By using the C3 medium, sphere-
forming or stem cell-like cancer cells fromHep3B (named as Hep3B-
C) (Fig. 1A) and Huh7-C (named as Huh7-C) (Fig. 1B) HCC cell lines
were successfully cultured and expanded. Stem cells are charac-
terized by their unique capability to keep self-renewal and
differentiation. Herein, we determined the self-renewal capacity of
sphere-forming cells by testing their capability for serial passage.
The spheres formed from Hep3B/Hep3B-EGF cells after being cul-
tured in C3 medium for 0, 10, 21, 23, 45, and 90 days were shown
in Fig. S1, and the results showed that spheres were formed and
the same status was maintained during the entire 3 month passage,
indicating their self-renewal capability in vitro.
Next, we cultured an additional three HCC cell lines, HCCLM3,
MHCC97-H andMHCC97-L, in the C3 medium. All of these cell lines
were able to form spheres that were stable during a long-term
culture. We named them as HCCLM3-C (Fig. 1C), MHCC97-H-C
(Fig. 1D) andMHCC97-L-C (Fig. 1E). It is critical to culture andmain-
tain stem cell-like cancer cells from primary tumor tissues for both
diagnostic and therapeutic purposes. Herein, we also successfully
established three cell lines with different characteristics from a
primary HCC tumor tissue and they were named EHBH-HCSC-1
(Fig. 1F), EHBH-HCSC-2 (Fig. 1G) and EHBH-HCSC-3 (Fig. 1H). These
cells grew well in the form of sphere for more than 3 months in
the C3 medium. We also evaluated the cell origin of these CSC-
like sphere-forming cancer cells by using glycogen staining (Fig. S2)
and ICG uptake experiments (Fig. S3) [17], and the results showed
that Hep3B-C and HuH7-C cells were originally fromHCC cells. Taken
together, these results demonstrated that the C3 culture system is
suitable for general in vitro culture and maintenance of various cell
lines and primary HCC cells that are of sphere-forming capability.
Differential expression of CSC biomarkers in sphere-forming
cancer cells
Comparedwith parental cells, HCC stem cell-like cancer cells have
unique characteristics as well as speciﬁc biomarkers. After the dem-
onstration of tumor-derived cells to organize self-renewing spheroids,
the expression of genes speciﬁc to tissue or embryonic stem cells
was examined. To further characterize the CSC-like cells, we used
qRT-PCR to detect the expression of CSC biomarkers such as CD90.
The results showed that themRNA expression level of CD90 (Fig. 2A),
Oct4 (Fig. 2G), and Nanog (Fig. 2H) was ubiquitously up-regulated,
while that of NOTCH1 (Fig. 2B), NOTCH2 (Fig. 2C), and NOTCH3
(Fig. 2D) were down-regulated in sphere-forming cells in compar-
isonwith that of parental cells. Generally, mRNA expression of Wnt-1
(Fig. 2E) and EpCAM (Fig. 2F) appeared to be down-regulated inmost
sphere-forming cells. We also analyzed the cell markers CD133 and
CD44, the results are shown in the supplementary materials (Fig.
S4). Flow cytometry analysis of CD90+ and EpCAM+ showed that the
CD90+ positive cells were signiﬁcantly enriched by about 5-fold in
Huh7-C, and 20-fold in Hep3B-C cells, while EpCam positive cells
dramatically decreased in both cell lines (Table S2), which indi-
cates that CSC-like cells were dramatically enriched in the cells
cultured in the C3 medium.
Differential expression of epithelial–mesenchymal transition (EMT)
markers in sphere-forming cancer cells
Recent studies indicate that the emergence of CSCs occurs in part
as a result of the EMT, and the activation of the EMT process has
been associated with the acquisition of stem cell traits by normal
and neoplastic cells [18]. In this study, we compared these epithe-
lial markers cytokeratins 8 and 18, as well E-cadherin and
mesenchymal cell surface marker vimentin [19] in parental and
sphere-forming cells by immunoﬂuorescence. Results showed that
the expression of cytokeratins 8/18 and E-cadherin were dramat-
ically decreased, while vimentin was up-regulated in two sphere-
forming cell lines, Huh7 (Fig. 3) and Hep3B (Fig. S5). Interestingly,
while these sphere-forming cells were cultured in serum-
supplementedmedium, the expression of these proteinswas restored
to levels similar to that of parent cells, suggesting a differentiation
process of these sphere-forming cells.
Sphere-forming cancer cells possess more invasive potential
Recent studies have identiﬁed the important role of CSCs in car-
cinogenesis and relapse. In several human cancers including HCC,
studies showed that some subsets of CSCs were responsible for
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cancer metastasis [6]. Herein, we used in vitro transwell assay to
compare the invasive potentials of sphere-forming cancer cells from
Huh7-C and Hep3Bwith that of their parental cells Huh7 and Hep3B,
respectively. The results of the invasion assay showed that more
Huh7-C (Fig. 4A, right panel) and Hep3B-C (Fig. 4B, right panel) cells
passed through the matrigel than their parental Huh7 (Fig. 4A, left
panel) and Hep3B cells (Fig. 4B, left panel), respectively. Quantita-
tive analysis demonstrated that the differences between the number
of invasive cells in Huh7-C (Fig. 4C) and Hep3B-C (Fig. 4D) and their
parental cells were signiﬁcant in statistics, indicating that the sphere-
forming cancer cells possess more invasive potential than their
parental cells in vitro.
Cell cycle and tumorigenic capacity of sphere-forming cancer cells
from HCC cell lines
Studies have indicated that some CSCs may switch between qui-
escent, slow-cycling status and active status, similar to the behavior
of many types of adult stem cells, and long-term quiescent/
dormant pools of human CSCs are present in cancer cells [20,21].
In line with these previous ﬁndings, we also found that 74.09% of
Hep3B-C and 88.15% of HuH7-C cells were in the G0–G1 phase, while
57.67% of parental Hep3B and 62.67% of parental HuH7 cells were
in the G0–G1 phase.
The tumorigenic potentials of the sphere-forming cells from four
HCC cell lines were accessed in vivo in immunodeﬁcient mice and
were compared with that of their parental cells. In the present study,
tumorigenicity is deﬁned as the capacity of a certain type of cell
with serial dilutions to form measurable xenograft tumor nodules
in immunodeﬁcient mice within 3 months. Tumor nodules ap-
peared 3 month after inoculation of 1 × 105 sphere-forming cells
derived from all four HCC cell lines, while the same number of HuH7
parental cells failed to form tumor nodules (Table 1), 1000 of Huh7
sphere-forming cells successfully formed tumor nodules in 1 out
of 5 mice. Once the cell number was decreased to 100, all paren-
tal cells of HCCLM3, MHCC97L andMHCC97H failed to generate any
tumor nodules, but their corresponding sphere-forming cells were
still capable to initiate the formation of tumor nodules in nude mice
with various positive incidences (Table 1). This result clearly dem-
onstrates that the sphere-forming cancer cells possessmuch stronger
tumorigenic potentials than their parental cells, indicating in-
creased stemness.
Fig. 1. Cells from 8 HCC cell lines formed the anchorage-independent, self-renewing spheres in C3 medium. Hepatoma cell lines Hep3B, Huh7, HCCLM3, MHCC97-H, (E)
MHCC97-L, EHBH-HCSC-1, EHBH-HCSC-2 and EHBH-HCSC-3 could form the anchorage-independent 3-D spheres in C3 medium for 2–3 months (200×). “-C” indicates sphere-
forming cells.
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Sphere-forming tumor cells are more resistant to doxorubicin
Accumulating pieces of evidence have suggested that CSCs are
commonly resistant to conventional chemotherapy and contrib-
ute to cancer recurrence [22]. To examine whether the self-renewing
sphere-forming cells have increased chemoresistance, the sensi-
tivity of the parental Huh7 cells and the tertiary sphere-forming cells
toward doxorubicin and sorafenibwas assessed. Comparedwith their
parental HuH7 cells, the sphere-forming cells were much more
resistant to doxorubicin (Fig. 5A) and sorafenib (Fig. 5B), as their IC50
values were signiﬁcantly higher than that of their parental Huh7
cells (p < 0.05). These results are in agreement with the common-
ly accepted concept that CSCs are chemoresistant and suggested the
signiﬁcant enrichment of stem cell-like cancer cell populations.
We also analyzed the Doxorubicin-inﬁltrated cells in both Hep3B
and HuH7 cancers by ﬂow cytometry. The results showed that after
exposure to 100 μM doxorubicin for 4 hours, the percentage of cells
sensitive to doxorubicin decreased after the enrichment, from 84.1%
Fig. 2. Expression of CSC-related genes in sphere-forming cells. qRT-PCR analysis showed that in comparison with their parental cells, sphere-forming cells Hep3B-C, Huh7-
C, MHCC97-L-C and HCCLM3-C showed differential expression of (A) CD90, (B) NOTCH1, (C) NOTCH2, (D) NOTCH3, (E) Ep-CAM, (F)Wnt-1, (G) Oct4 and (H) Nanog. All experiments
were repeated 3 times. Data are the mean ± SD. * P < 0.05; ** P < 0.01, compared with parent cells.
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(Fig. 5C) in parental Huh7 cells down to 34.5% (Fig. 5D) in corre-
sponding sphere-forming cancer cells, and from 91.3% (Fig. 5E) in
parental Hep3B cells down to 77.6% (Fig. 5F) in the sphere-forming
cancer cells. This result suggests that the intake of the drugs by the
sphere-forming cancer cells is less than that of their parental cancer
cells at the same drug concentration, and may partially explain the
high level drug resistance in HCSCs.
RNAseq analysis of differential expression of genes and miRNAs in
sphere-forming cells
To further verify the enrichment of stem-like cancer cells, RNAseq
was used to proﬁle genes and miRNAs differentially expressed in
sphere-forming cells and their parental Hep3B, Huh7 andMHCC97-H
cells. We identiﬁed 406 differentially expressed genes overlapped
among groups via fold change method (Table S3). It was found that
90 genes were up-regulated and 316 genes were down-regulated.
Heat map shows the clustering of all the signiﬁcant genes (Fig. 6A).
In order to validate themicroarray results, we selected several highly
differentially expressed genes in Table S3 for validation by RT-
PCR. The expression patterns of 9 genes were conﬁrmed by
RT-PCR and are shown in Fig. 6B. In order to identify the function-
al classiﬁcation of these 406 genes, we performed functional
enrichment analysis in the GeneOntology database. The analysis
showed that dys-regulated genes in stem-like cancer cells were as-
sociated with biological signaling pathways such as the TGF-beta
pathway, cell adhesion (PTPRM), PPAR signaling pathway (FADS2),
biosynthesis of un-saturated fatty acids (FASN).
During the last decade, it has become clearer that alterations in
the expression of several miRNAs are extensively associated with
the stemness of CSCs of many human cancers including HCC [23].
Herein, we also revealed the differential expression of miRNAs in
sphere-forming cancer cells of Hep3B and Huh7 in comparison with
their parental cells. Heat map shows the clustering of all the sig-
niﬁcant genes (Fig. 6C). We identiﬁed, through RNAseq, 18
differentially expressed miRNAs in two sphere-forming cancer cell
lines compared with their parental cells. Of them, 9 miRNAs were
found up-regulated including miR-450b-5p, miR-478d, miR-375,
miR-215, miR-378, miR-760, miR-1296b and miR-1269; and the
other 9 miRNAs were downregulated including miR-210, miR-
15b*, miR-100, miR-181c, miR-29c, miR-149, miR-199a-3p, miR-
199b-3p and miR-22, (Table S4). In order to validate the RNAseq
Fig. 3. Immunoﬂuorescence staining of epithelial and EMT markers on sphere-forming cell HuH7-C. Immunoﬂuorescence staining showed decreased expression of CK8/18
and E-cadherin, and elevated expression of Vimentin in sphere-forming cells Huh7-C and in C3 medium, and the changes were reversed after the cells were cultured in
serum-supplemented medium. “-C” indicates sphere-forming cell, and “-C-D” is for sphere-forming cells that were cultured in the medium with serum.
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results, we selected several miRNAs that were highly differentially
expressed in Table S3 for validation by RT-PCR. The differential ex-
pressions of the 8 selected miRNAs were all conﬁrmed by RT-PCR
(Fig. 6D). Furthermore, we also identiﬁed miR-15b to be signiﬁ-
cantly downregulated, and miR-215 to be signiﬁcantly up-regulated
in two HCC sphere-forming cancer cells. Interestingly, a recent study
has identiﬁedmiR-15b that inhibits CSC growth to be downregulated
in breast CSCs [24]. Another study further demonstrated that miR-
15b regulated chemotherapy-induced EMT in human tongue cancer
cells by targeting BMI1 [25]. Studies also demonstrated that miRNA-
215 enhances the chemoresistance of CD133 high-CD44 high colon
cancer cells to methotrexate and tomudex by inhibiting cell pro-
liferation and inducing G2-arrest through the suppression of DTL
expression [26].
Discussion
The TIC model of HCC formation has gained popularity recently
because it provides the explanation to HCC resistance to radiation and
chemotherapy, which is a major problem in HCC treatment. Based on
this model, the resistance of HCC to radiochemotherapy is due to the
existence of a subpopulation of theHCC cells that possess the stem cell
characteristics, but are still capable of causing the heterogeneous
lineages of cancer cells that constitute the tumor. Despite the evi-
dence supporting the existence of such a subpopulation of stem-like
cancer cells in various cancers, due to the lack of clearly demon-
strated isolation of CSCs, controversies remain about the prospects of
application of the TIC model in cancer therapy.
To better understand the formation of HCC in order to ﬁnd ef-
fective approaches to treat liver cancer, there is a clear need to
establish an in vitro model that allows the culture and expansion
of the stem-like cancer cells. Various methods have been em-
ployed in an attempt to isolate and enrich the HCSCs. Immuno-
chemical selection based on the cell surface biomarkers is one of
themost commonly usedmethods. These biomarkers include CD133,
CD90 and EpCAM. However, the deﬁnitive markers for HCSC selec-
tion have yet been identiﬁed as it has been found that not all these
markers are enriched on the surfaces of the same subset of cells.
The difference of dye eﬄux properties in cancer cells is also em-
ployed to distinguish HCSCs from differentiated HCC cells. But at
least in the case of Hoechst 33342, concerns arose as the enrich-
ment of SP cells may be a result of Hoechst 33342 toxicity to the
non-SP cells whose growth was suppressed by the drug. Physical
properties of the HCC cells such as cell density were also applied
in TIC selection [8], but the method does not allow the expansion
and enrichment of the HCSC subpopulation.
Fig. 4. Enhanced invasive potential in sphere-forming cells Huh7-C and Hep3B-C. Representative photomicrographs showed sphere-forming cells (right panel) of (A) Huh7-C
and (B) Hep3B-C that have invaded through matrigel compared with their parent cells (left panel). Quantitative analysis of invaded cells from sphere-forming cells (C) Huh7-C
and (D) Hep3B-C was presented as mean values graphed for indicated cells (n = 3 replicates per cell type). Error bars show SD (**p < 0.01, compared with parental cells).
Table 1
Comparison of tumorigenic capacity of parental and sphere-forming cells from different HCC cell lines.
Cell lines MHCC97-H MHCC97-H-C MHCC97-L MHCC97-L-C HCCLM3 HCCLM3-C Huh7 Huh7-C
105 5/5 5/5 3/5 5/5 4/5 5/5 0/5 5/5
104 0/5 4/5 1/5 5/5 2/5 5/5 0/5 3/5
103 1/5 3/5 1/5 5/5 1/5 0/5 0/5 1/5
102 1/5 5/5 2/5 0/5
Tumor nodules appeared 3 months after inoculation of 1 × 105 sphere-forming cells derived from all four HCC cell lines, while the same number of HuH7 parental cells
failed to form tumor nodules (Table 1), 1000 of Huh7 sphere-forming cells successfully formed tumor nodules in 1 out of 5 mice. Once the cell number was decreased to
100, all parental cells of HCCLM3, MHCC97L and MHCC97H failed to generate any tumor nodules, but their corresponding sphere-forming cells were still capable to initiate
the formation of tumor nodules in nude mice with various positive incidence.
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The approach that uses deﬁned serum-free media has been a
powerful method to select and enrich HCSCs, and has many ad-
vantages over other methods. The approach deﬁnes the in vitro
conditions that allow the predictable selection and expansion of
HCSCs without pre-selection, thus eliminating the problem asso-
ciated with the various expression patterns of cell surface markers
found on different subpopulations of HCSCs. Furthermore, strong
evidence has suggested that the microenvironment plays an im-
portant role in the initiation and progression of cancer [27,28]. The
deﬁned serum-free system is therefore especially useful in under-
standing the role of the HCSCs in the formation of HCC, and
development of approaches that may bemore effective in HCC treat-
ment and reduction of the post therapy recurrence of cancer. The
deﬁned serum-free media also allow expansion of the HCSCs, and
the expanded cells can be used as screening tools for research and
drug discovery [29].
In this study, after extensive screening, we have developed a
deﬁned serum-free medium and demonstrated that it is effective
in HCSC expansion and enrichment. This medium contains DMEM/
F12, Neurobasal-Amedium, B27without VA, EGF, the cytokines FGF-
10 and IGF-1 and was named as C3 medium. The sphere-forming
cancer cells from both HCC cell lines and human primary HCC could
be enriched and expanded in the medium. Analyses of stem cell
biomarker mRNAs showed that in comparison with their parental
cells, the sphere-forming cancer cells cultured in this medium have
higher levels of CD90 expression, and decreased expressions of
NOTCH1, 2 and 3, as well as Wint-1 and EpCAM, indicating the en-
richment of cancer cells with stem cell characteristics (stem-like
cancer cells). Recent studies indicate that CSC is a result of dedif-
ferentiation from cancer cells, a process resembling EMT; we also
examined some EMTmarkers on these sphere-forming cancer cells,
and found that the expression of cytokeratins 8/18 and E-cadherin
decreased dramatically, and vimentin was up-regulated, indicat-
ing the gain of mesenchymal cell markers. Moreover, in vitro
transwell assay showed that the sphere-forming cancer cells possess
more invasive potential than their parental cells, a result in accor-
dance with the observation that some CSCs promote metastasis [6].
As resistance to chemotherapeutic agents is a widely accepted char-
acteristic of CSCs [22], we also examined the resistance of these
sphere-forming cancer cells to doxorubicin and sorafenib. As dem-
onstrated by the IC50s, the sphere-forming cancer cells are more
resistant to both drugs. Since the ultimate criterion in verifying the
stemness of cancer cells is their tumor-initiating ability [30], we also
analyzed the abilities of these sphere-forming cells to initiate tumor
in immunodeﬁcient mice. It was found that these sphere-forming
cancer cells have much higher capacity in the initiation of xeno-
graft tumor nodules than that of their parental cells, with as low
as 100 cells being able to initiate the formation of the tumor nodules.
This result strongly suggested that the enriched sphere-forming cells
are indeed HCSCs.
We also analyzed the gene expression pattern in both the sphere-
forming cancer cells and their parental cells. Results showed that
406 genes were expressed differentially, with 90 genes up-regulated
and the rest 316 genes down-regulated. Further analysis revealed
that the down-regulated genes are associated with pathways such
as the TGF-beta pathway, cell adhesion, PPAR signaling pathway, and
biosynthesis of unsaturated fatty acids. The signiﬁcance of the dif-
ferential gene expression proﬁle is subject to future study. Recent
studies have also shown that miRNAs play an important role in CSCs
[23]. To gain an insight into the regulation of the enrichment of the
Fig. 5. Resistance of the sphere-forming cells to anti-cancer drugs. (A and B) Compared with parental HuH7 cells, the sphere-forming cells were much more resistant to
doxorubicin (A) and sorafenib (B), and their IC50 values were signiﬁcantly higher than those of the parental Huh7 cells. Data were presented as mean ± SD of three inde-
pendent experiments in duplicates (*P < 0.05 and **p < 0.01, compared with parental cells). Subpopulation of sphere-forming cells and parent cells of (C and D) Huh7 and (E
and F) Hep3B positive for doxorubicin after being cultured with 100 μm doxorubicin for 4 h, and then measured by FACS.
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HCSCs, we compared the proﬁles of the expression of miRNAs in
the sphere-forming cancer cells with those of their parental cells.
Analysis showed the up-regulation of 9miRNAs and down-regulation
of another 9 miRNAs. One of down-regulated miRNAs is miR-15b
which has been shown to inhibit the growth of CSCs and is also
down-regulated in breast CSCs [24].
To better understand the etiology of HCC and develop effective
anti-cancer approaches, there is a clear need of in vitro model
systems for the study of the HCSCs. In the general CSC ﬁeld, cancer
stem cells have been established by using markers or the unique
physical and chemical properties of stem cells to separate subpopu-
lations from existing tumor lines. In our study, CSCs were selected
from tumors or tumor cell lines using deﬁned serum-free condi-
tions. In this medium, we gained a group of cells which showed
typical stem cell properties. However, whether liver cancer stem cells
are just one kind of cell or a group of cells, do they have very deﬁned
surface markers? Are cancer stem cells in a relatively stable state
or in a process of changing? All of these questions need to be ex-
plored with continuous efforts. Fortunately, we are getting more and
more closer to the goal.
Taken together, we have successfully developed a medium
that has enabled us to effectively enrich the population of
sphere-forming cancer cells from both hepatoma and human primary
HCC cells. These cells exhibited typical stem cell properties, such
as enhanced stem cell markers, gain of EMT properties and drug
resistance, and more importantly, stronger tumor-initiating capa-
bilities. Targeting HCSCs may bring hope in curing HCC, but the
progress on HCSC research has been slow largely due to the diﬃ-
culties either in identifying these HCSCs in liver cancers or in isolating
such HCSCs. Our culture system makes it possible to study HCSCs
in vitro, whichmay contribute to the development of novel cell thera-
pies and new drugs for the treatment of HCC.
Conclusions
We established a novel culture system that enlarged these hepatic
stem-like cancer cells from both hepatoma cells and human primary
HCC cells. These cells showed typical stem cell properties, such as
enhanced stem cell markers, gain of EMT properties and drug re-
sistance, andmore importantly, stronger tumor-initiating capabilities.
The culture systemmay help to establish an in vitromodel for hepatic
cancer stem cell (HCSC) studies, which may contribute to the de-
velopment of novel cell therapies and new drugs for the treatment
of HCC.
Fig. 6. Genes differentially expressed in the sphere-forming cells and their parental cells. (A) The heat map shows the clustering of all the signiﬁcant genes (22 genes) by
RNAseq analysis. (B) Nine selected genes that were differentially expressed were validated by qRT-PCR. The results were consistent with the data of RNAseq. (C) The heat
map shows the clustering of all the signiﬁcant miRNA (18 miRNA) by RNAseq analysis. (D) Differentially expressed miRNAs were identiﬁed by RNAseq and validated by
qRT-PCR. The mRNA expression of each gene or miRNA was presented as the ratio to reference gene and small RNA. Data were presented as mean ± SD of three indepen-
dent experiments in triplicates. * P < 0.05; ** P < 0.01, compared with parental cells.
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